Related Experiment Videos
Clinical experience with amikacin, a new aminoglycoside antibiotic
Abstract:
Amikacin, a new semisynthetic aminoglycoside antibiotic, was administered parenterally to 20 patients suffering from severe Gram-negative bacterial infections. The antibiotic was found to be highly effective in controlling infection. It was well tolerated and no signs of nephro- or otoxicity were observed. The few side-effects which were seen appeared to be dose-related. The recommended 12-hourly dosage regimen has also proved useful in medium- to long-term management of refractory pulmonary infections.
Insights
Amikacin, a novel aminoglycoside antibiotic, effectively treated severe Gram-negative infections in 20 patients. This antibiotic demonstrated good tolerability with no observed nephrotoxicity or ototoxicity, proving beneficial for long-term pulmonary infection management.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Severe Gram-negative bacterial infections pose significant therapeutic challenges.
- Development of novel antibiotics is crucial for combating resistant pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of amikacin in patients with severe Gram-negative bacterial infections.
- To assess the tolerability and side-effect profile of amikacin.
- To determine the suitability of amikacin for long-term management of refractory infections.
Main Methods:
- Parenteral administration of amikacin to 20 patients.
- Clinical assessment of infection control.
- Monitoring for adverse effects, including nephrotoxicity and ototoxicity.
- Evaluation of a 12-hourly dosage regimen for long-term use.
Main Results:
- Amikacin demonstrated high effectiveness in controlling severe Gram-negative bacterial infections.
- The antibiotic was well tolerated by patients.
- No instances of nephrotoxicity or ototoxicity were observed.
- Observed side-effects were infrequent and appeared dose-related.
- The 12-hourly dosage regimen proved effective for medium- to long-term management of refractory pulmonary infections.
Conclusions:
- Amikacin is a highly effective and well-tolerated antibiotic for severe Gram-negative bacterial infections.
- Its safety profile, particularly the absence of nephro- and ototoxicity, is advantageous.
- Amikacin offers a viable therapeutic option for the long-term management of challenging pulmonary infections.